https://scholars.lib.ntu.edu.tw/handle/123456789/372627
Title: | Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: An open-label pilot study | Authors: | HUEY-LING CHIANG Yang, Ya-Hsu Lin, Jen-Kou Chen, Wei-Shone Lin, Tzu-Chen Yang, Shung-Haur Jiang, Jeng-Kai Chang, Shih-Ching Lan, Yuan-Tzu Lin, Chun-Chi Yen, Chueh-Chuan Tzeng, Cheng-Hwai Wang, Wei-Shu Chiang, Huey-Ling Teng, Chung-Jen Teng, Hao-Wei |
Keywords: | Duloxetine; Oxaliplatin; Peripheral neuropathy; Serotonin and norepinephrine reuptake inhibitor (SNRI); Supportive care | Issue Date: | 2012 | Journal Volume: | 20 | Journal Issue: | 7 | Start page/Pages: | 1491-1497 | Source: | Supportive Care in Cancer | Abstract: | Background This open-label pilot study is aimed to evaluate the efficacy and tolerability of the antidepressant duloxetine, which is effective for diabetic neuropathic pain, in the treatment of chronic oxaliplatin-induced peripheral neuropathy (OIPN). Methods We enrolled a total of 39 patients with stage III or IV colorectal cancer with chronic OIPN. They were treated with duloxetine by increasing the dose from 30 mg/day to 60 mg/ day. Patients' pain intensity was rated at baseline and 12 weeks after duloxetine administration. The severity of neuropathic pain was evaluated using the visual analog scale (VAS) score and the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3 (NCI-CTCAE v3.0). Results Nine patients (23.1%) discontinued duloxetine before the end of treatment because of adverse events. Of the remaining 30 patients, 19 patients (63.3%) had a VAS score improvement. Among them, nine (47.4%) showed a simultaneous grade improvement, and the other 10 patients (52.6%) had a stable grade according to NCI-CTCAE v3.0. Treatment with duloxetine did not impair renal or liver function and did not interfere with chemotherapy. Conclusions Duloxetine is feasible in treating chronic OIPN with tolerable toxicity at a daily dose of 60 mg/day. ? 2011 Springer-Verlag. |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84863980681&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/372627 |
DOI: | 10.1007/s00520-011-1237-2 | SDG/Keyword: | alanine aminotransferase; albumin; bilirubin; capecitabine; creatinine; duloxetine; fluorouracil; folinic acid; oxaliplatin; adult; aged; alanine aminotransferase blood level; albumin blood level; article; bilirubin blood level; cancer chemotherapy; cancer staging; clinical article; clinical trial; colorectal cancer; creatinine blood level; disease severity; dizziness; drug dose escalation; drug dose increase; drug efficacy; drug fatality; drug safety; drug tolerability; drug withdrawal; feasibility study; female; human; insomnia; kidney function; liver function; male; National Cancer Institute Common Toxicity Criteria for Adverse Events version 3; nausea; open study; pain assessment; peripheral neuropathy; pilot study; priority journal; restlessness; scoring system; side effect; somnolence; treatment duration; treatment response; urinary hesitancy; visual analog scale; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antineoplastic Agents; Colorectal Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Severity of Illness Index; Thiophenes |
Appears in Collections: | 醫學系 |
File | Description | Size | Format | |
---|---|---|---|---|
index.html | 23.17 kB | HTML | View/Open | |
52.pdf | 188.19 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.